VCP
MYGN icon

Verus Capital Partners’s Myriad Genetics MYGN Stock Holding History

Verus Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$6K Hold
400
– – ﹤0.01% 1141
2019
Q4 		$11K Buy
+400
New +$11K ﹤0.01% 1093

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verus Capital Partners's MYGN Position: Q1 2020 in Review

Verus Capital Partners held its Myriad Genetics (MYGN) position steady in Q1 2020 at 400 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Verus Capital Partners first reported a position in MYGN in Q4 2019 and has held it in 2 quarters since. The position peaked at $11K in Q4 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Verus Capital Partners held 400 shares of Myriad Genetics worth $6K as of Q1 2020.
  • Verus Capital Partners left its Myriad Genetics share count unchanged in Q1 2020.
  • Myriad Genetics made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1141 holding.
  • Verus Capital Partners first reported a position in Myriad Genetics in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Myriad Genetics position peaked at $11K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.